オプションチェーンは、Nuvalentの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Nuvalentの市場センチメントを評価します。.

Nuvalent (NASDAQ:NUVL) 株価情報, オプションチェーン

Nuvalent

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

News

Movers

ACLS

AGIO

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？

直近1週間高パフォーマンスを示したのは、中型株

Nuvalent Inc

The deal priced below last closing price of $102.51. JPMorgan is acting as sole book running manager for the offering. Published first on TheFly – ...

Nuvalent 2M share Spot Secondary priced at $99.00

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

Nuvalent GAAP EPS of $1.28

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Nuvalent (NUVL – Research Report) and keeping the price target at $110.00. Char...

Nuvalent: Strategic Progress and Pipeline Advancements Solidify Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Prime Medicine, Inc. (PRME – Research Report) and Nu...

Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Nuvalent (NUVL)

Nuvalent, Inc. Class A ( ($NUVL) ) has released its Q3 earnings. Here is a breakdown of the information Nuvalent, Inc. Class A presented to its inv...

Nuvalent Reports Q3 2024 Progress and Financials

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Nuvalent (NUVL – Research Report), with a price target of $100.00...

Barclays Remains a Buy on Nuvalent (NUVL)

Analyst Etzer Darout of BMO Capital maintained a Buy rating on Nuvalent (NUVL – Research Report), boosting the price target to $134.00. Etzer Darou...

Nuvalent's Promising Pipeline and Strategic Advancements Justify Buy Rating

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Nuvalent (NUVL – Research Report), with a price target o...

Nuvalent (NUVL) Receives a Buy from Stifel Nicolaus

BPMC

CATX

CGEM

CGON

HAFC

IDYA

IMCR

IOVA

JANX

KURA

MRUS

NRIX

PRME

SIRI

SNDX

Press Releases

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Offerings

Nuvalent Announces Public Offering of Common Stock

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update

Earnings

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

NVCT

SMMT

ADMA Biologics

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biohaven

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Vaxcyte

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Comments

Nuvalent

Nuvalent (NUVL) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル